Answer
Aripiprazole’s efficacy in schizophrenia and bipolar I disorder is proposed to be mediated by partial agonism at dopamine D2 and serotonin 5-HT1A receptors combined with antagonism at serotonin 5-HT2A receptors.
Sources for this answer
- Abilify 7.5 mg/ml solution for injection (intramuscular)Otsuka Pharmaceuticals (UK) Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 34Document updated
Sources checked